['psoriasis']
['bay1003803', 'clobetasol propionate', 'betamethasone/calcipotriene']

        Inclusion Criteria:

          -  Male and female (non-childbearing potential) volunteer with stable plaque-type
             psoriasis, but otherwise healthy

          -  Age: 18-64 years

        Exclusion Criteria:

          -  Severe disease within the last 4 weeks prior to the first study drug administration as
             determined by the investigator

          -  Any topical antipsoriatics on plaques potentially to be treated in this trial
             (including corticosteroids, vitamin D analogues, immunomodulators, retinoids,
             dithranol and tar, except for salicylic acid (Pretreatment) in the 4 weeks before
             first treatment and/or planned during the trial, except for allowed topical treatment
             on the face, ears and scalp

          -  Systemic treatment depending on kind of treatment within 4 weeks and 6 months prior
             and/or planned during the trial

          -  Treatment with concomitant medication that may affect and provoke or aggravate
             psoriasis, e.g. antimalarial drugs, lithium, beta-blockers or
             angiotensin-converting-enzyme inhibitors (AEC inhibitors) unless on a stable dose for
             3 months before study medication initiation

          -  Clinico-chemical parameters of clinically significant deviation
      